Urinary Tract Infection Market Research Report—Forecast till 2027

Urinary Tract Infection Market Research Report—Forecast till 2027

$4450 – $6250

Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection.

SKU: MRFR210099 Category: Tags: , , , , , , , , , ,

Description

Urinary Tract Infection Market Research Report—Forecast till 2027

Market Overview
Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection. The major causes of UTI infection are unsafe sex, lack of hygiene, and diabetes.
Global Urinary Tract Infections Market is expected to register the highest market growth owing to the largest market value of USD 9,490.88 Million in 2019. As per the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affect almost half the female population around the world. Urological health issues are more common in diabetic patients. An increasing prevalence of diabetic population is expected to boost the global UTI patients worldwide. However, complex regulatory requirements are anticipated to restrain the growth of the global urinary tract infection market during the review period.
Market Segmentation
Global Urinary Tract Infections Market has been segmented into Drug Class, Application, Pathogen, End User.
In terms of drug class, the market has been classified into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones segment is further sub-divided into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is again classified into avycaz, cedax, cefdinir, and cefditoren. The β-lactam is further divided into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.
The Global Urinary Tract Infections Market, based on application, has been divided into urethritis, cystitis, and pyelonephritis. In terms of the pathogen, the market has been categorized into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. By end-user category, the global urinary tract infections market has been classified into hospitals, clinics, self-administered, and others.
Regional Analysis
Geographically, the global UTI market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global market owing to the largest market share of 33.6% of the global market in 2019. The regional market growth is driven by the presence of key manufacturers, the increasing prevalence of urinary tract infections, and the increasing aging woman population in the region. The market in the Americas is categorized into North America and Latin America. Additionally, the global market growth is driven by the increasing technological advancements in diagnostics and therapeutic products coupled with the rising prevalence of urinary tract diseases and other kidney problems.
Europe is expected to register the second-largest market of the Global Urinary Tract Infection. The regional market is segmented into France, Germany, Italy, Spain, and the UK. The regional market growth is attributed to the increasing awareness of urinary tract diseases, increasing educational activity, and the availability of different diagnostic and therapeutic methods to manage the infection. Asia-Pacific is set to exhibit the fastest-growing market for UTI during the review period. The regional market growth is driven by the developing economies and highly populated countries such as China, India, and South Korea.
Major Players
The Prominent Players in the Global Urinary Tract Infections Market are Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 MARKET ATTRACTIVENESS ANALYSIS 18 2 MARKET INTRODUCTION 2.1 DEFINITION 19 2.2 SCOPE OF THE STUDY 19 2.3 RESEARCH OBJECTIVE 19 2.4 MARKET STRUCTURE 19 2.5 ASSUMPTIONS & LIMITATIONS 20 3 RESEARCH METHODOLOGY 3.1 DATA MINING 21 3.2 SECONDARY RESEARCH 22 3.3 PRIMARY RESEARCH 23 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24 3.5 FORECASTING TECHNIQUES 25 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26 3.6.1 BOTTOM-UP APPROACH 27 3.6.2 TOP-DOWN APPROACH 27 3.7 DATA TRIANGULATION 28 3.8 VALIDATION 28 4 MARKET DYNAMICS 4.1 OVERVIEW 29 4.2 DRIVERS 30 4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30 4.2.2 LAUNCH OF COMBINATION DRUGS 30 4.3 RESTRAINTS 31 4.3.1 COMPLEX REGULATORY REQUIREMENTS 31 4.4 OPPORTUNITIES 32 4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 33 5.1.1 R&D AND DESIGNING 34 5.1.2 MANUFACTURING 34 5.1.3 DISTRIBUTION & SALES 34 5.1.4 POST-SALES SERVICES 34 5.2 PORTER’S FIVE FORCES MODEL 35 5.2.1 BARGAINING POWER OF SUPPLIERS 36 5.2.2 BARGAINING POWER OF BUYERS 36 5.2.3 THREAT OF NEW ENTRANTS 36 5.2.4 THREAT OF SUBSTITUTES 36 5.2.5 RIVALRY 36 5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37 5.3.1 OVERVIEW 37 5.3.2 IMPACT ON SUPPLY CHAIN 37 5.3.3 IMPACT ON PRODUCTION 38 6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS 6.1 OVERVIEW 40 6.2 QUINOLONES 42 6.3 Β-LACTAM & CEPHALOSPORINS 43 6.4 AMINOGLYCOSIDES 44 6.5 PENICILLIN 44 6.6 AZOLES 45 7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION 7.1 OVERVIEW 46 7.2 URETHRITIS 47 7.3 CYSTITIS 48 7.4 PYELONEPHRITIS 48 8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN 8.1 OVERVIEW 49 8.2 ESCHERICHIA COLI 50 8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51 8.4 KLEBSIELLA PNEUMONIAE 51 8.5 PROTEUS MIRABILIS 52 8.6 ENTEROCOCCUS FAECALIS 52 9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER 9.1 OVERVIEW 53 9.2 HOSPITALS 54 9.3 CLINICS 54 9.4 SELF-ADMINISTERED 55 10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION 10.1 OVERVIEW 56 10.2 AMERICAS 58 10.2.1 NORTH AMERICA 61 10.2.1.1 US 64 10.2.1.2 CANADA 67 10.2.2 LATIN AMERICA 70 10.3 EUROPE 73 10.3.1 WESTERN EUROPE 76 10.3.1.1 GERMANY 80 10.3.1.2 FRANCE 83 10.3.1.3 UK 86 10.3.1.4 ITALY 89 10.3.1.5 SPAIN 92 10.3.1.6 REST OF WESTERN EUROPE 95 10.3.2 EASTERN EUROPE 98 10.4 ASIA-PACIFIC 101 10.4.1 CHINA 105 10.4.2 INDIA 108 10.4.3 JAPAN 111 10.4.4 AUSTRALIA 114 10.4.5 SOUTH KOREA 117 10.4.6 REST OF ASIA-PACIFIC 120 10.5 MIDDLE EAST & AFRICA 123 10.5.1 MIDDLE EAST 126 10.5.2 AFRICA 129 11 COMPETITIVE LANDSCAPE 11.1 OVERVIEW 132 11.2 COMPETITIVE BENCHMARKING 133 11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2019 134 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134 11.4.1 PRODUCT APPROVALS AND LAUNCHES 134 11.4.2 ACQUISITIONS 134 11.5 FINANCIAL MATRIX 135 12 COMPANY PROFILES 12.1 PFIZER INC. 136 12.1.1 COMPANY OVERVIEW 136 12.1.2 FINANCIAL OVERVIEW 137 12.1.3 PRODUCTS/SERVICES OFFERED 138 12.1.4 KEY DEVELOPMENTS 138 12.1.5 SWOT ANALYSIS 138 12.1.6 KEY STRATEGIES 139 12.2 NOVO NORDISK A/S 140 12.2.1 COMPANY OVERVIEW 140 12.2.2 FINANCIAL OVERVIEW 140 12.2.3 PRODUCTS/SERVICES OFFERED 141 12.2.4 KEY DEVELOPMENTS 141 12.2.5 SWOT ANALYSIS 141 12.2.6 KEY STRATEGIES 141 12.3 NOVARTIS AG 142 12.3.1 COMPANY OVERVIEW 142 12.3.2 FINANCIAL OVERVIEW 142 12.3.3 PRODUCTS/SERVICES OFFERED 143 12.3.4 KEY DEVELOPMENTS 143 12.3.5 SWOT ANALYSIS 143 12.3.6 KEY STRATEGIES 144 12.4 MERCK & CO., INC. 145 12.4.1 COMPANY OVERVIEW 145 12.4.2 FINANCIAL OVERVIEW 145 12.4.3 PRODUCTS/SERVICES OFFERED 146 12.4.4 KEY DEVELOPMENTS 146 12.4.5 SWOT ANALYSIS 146 12.4.6 KEY STRATEGIES 146 12.5 ELI LILY AND COMPANY 147 12.5.1 COMPANY OVERVIEW 147 12.5.2 FINANCIAL OVERVIEW 147 12.5.3 PRODUCTS/SERVICES OFFERED 148 12.5.4 KEY DEVELOPMENTS 148 12.5.5 SWOT ANALYSIS 148 12.5.6 KEY STRATEGIES 148 12.6 ALLERGAN 149 12.6.1 COMPANY OVERVIEW 149 12.6.2 FINANCIAL OVERVIEW 149 12.6.3 PRODUCTS/SERVICES OFFERED 150 12.6.4 KEY DEVELOPMENTS 150 12.6.5 SWOT ANALYSIS 150 12.6.6 KEY STRATEGIES 150 12.7 CIPLA INC. 151 12.7.1 COMPANY OVERVIEW 151 12.7.2 FINANCIAL OVERVIEW 151 12.7.3 PRODUCTS/SERVICES OFFERED 151 12.7.4 KEY DEVELOPMENTS 151 12.7.5 SWOT ANALYSIS 152 12.7.6 KEY STRATEGIES 152 12.8 TEVA PHARMACEUTICALS 153 12.8.1 COMPANY OVERVIEW 153 12.8.2 FINANCIAL OVERVIEW 153 12.8.3 PRODUCTS/SERVICES OFFERED 154 12.8.4 KEY DEVELOPMENTS 154 12.8.5 SWOT ANALYSIS 154 12.8.6 KEY STRATEGIES 155 12.9 GLAXOSMITHKLINE PLC 156 12.9.1 COMPANY OVERVIEW 156 12.9.2 FINANCIAL OVERVIEW 156 12.9.3 PRODUCTS/SERVICES OFFERED 157 12.9.4 KEY DEVELOPMENTS 157 12.9.5 SWOT ANALYSIS 157 12.9.6 KEY STRATEGIES 157 12.10 BAYER AG 158 12.10.1 COMPANY OVERVIEW 158 12.10.2 COMPANY VALUE 158 12.10.3 FINANCIAL OVERVIEW 159 12.10.4 PRODUCTS/SERVICES OFFERED 159 12.10.5 KEY DEVELOPMENTS 159 12.10.6 SWOT ANALYSIS 160 12.10.7 KEY STRATEGIES 160 13 APPENDIX 13.1 REFERENCES 161 13.2 RELATED REPORTS 161

Reviews

There are no reviews yet.

Be the first to review “Urinary Tract Infection Market Research Report—Forecast till 2027”

Related products